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There are wide variations in the susceptibility of humans, animals, and cultured cell lines to infection by prions. In this issue of The EMBO Journal, Marbiah et al (2014) identified a gene regulatory network that regulates the susceptibility of cultured cells to prion infection. Surprisingly, a number of these genes impact the structure of the extracellular matrix. These results have important implications for understanding mechanisms of prion infection and also suggest new therapeutic targets.
See also: MM Marbiah et al (July 2014) P rion diseases are transmissible neurodegenerative disorders of humans and animals characterized by dementia, motor dysfunction, and the accumulation of an abnormal isoform of the prion protein (PrP Sc ) in the central nervous system. PrP Sc is an infectious protein that propagates itself via its ability to promote conversion of PrP C (the normal, cellular form of the prion protein) into additional PrP Sc molecules via a sequence-specific, templating mechanism (Prusiner, 1998) . Examples of prion disorders include Creutzfeldt-Jakob disease and kuru in humans, scrapie in sheep, and bovine spongiform encephalopathy in cattle. A number of factors control susceptibility to prion diseases, most notably the endogenous gene that encodes PrP C . Mice that lack PrP C are completely resistant to prion infection (Bü eler et al, 1993) , and coding polymorphisms in the PrP C gene affect disease susceptibility and incubation times in animals and humans (Westaway et al, 1987; Collinge et al, 1996) . However, it is clear from genetic studies in mice and humans that additional, non-PrP loci affect incubation times and susceptibility to infection (Lloyd et al, 2013 (Butler et al, 1988) . Amazingly, from a single cell line, it is possible to isolate some subclones that are highly infectible, as well as other subclones that are almost totally resistant to infection (Klohn et al, 2003) . Importantly, these differences are not correlated with PrP expression levels and are presumably due to genetic or and/or transcriptional differences that are inherited within each subclone. Until now, there was very little insight into the molecular factors that control these variations in susceptibility. Identifying these factors is of great importance, both for understanding basic pathogenic mechanisms and for developing effective therapies. Genes and proteins that influence prion susceptibility represent potential new targets for treatment of these invariably fatal diseases. In this paper, Marbiah et al (2014) employed a clever strategy to elucidate a gene regulatory network that controls prion infectibility in cultured cells. The authors used different subclones of N2a neuroblastoma cells that are either susceptible or resistant to infection by a particular prion strain. Using transcriptional profiling, they compared three subclones that are susceptible to prion infection with three other ones that are resistant (called revertants because they were derived from susceptible N2a cells). Employing this approach, they identified a set of 95 genes that are differentially expressed in the two groups. Based on their observations that this set was enriched in genes involved in cellular differentiation and development and that the susceptible cells over-expressed genes that promoted a differentiated phenotype, the authors tested the effect of the pro-differentiation agent, retinoic acid, on prion infectibility. Treatment of resistant subclones with retinoic acid increased prion propagation up to 40-fold, rendering the cells highly susceptible to infection.
The authors then used this phenomenon as the basis for an additional filter to identify relevant genes. They first compared the transcriptional signatures of the resistant cells treated or not with retinoic acid and identified 97 genes that were over-expressed in the treated group. They then compared this list of genes with the list of 95 genes identified from their original analysis of susceptible vs. resistant subclones, yielding a small set of 18 overlapping genes that were found on both lists. They proceeded to validate this set of genes, first by quantitative, real-time PCR, and then functionally using shRNA-mediated knockdown. Strikingly, knockdown of any one of 9 genes in prion-resistant cells caused the cells to become several-fold more susceptible to infection. These genes included fibronectin 1 (Fn1), integrin a8 (Itga8), chromogranin A (Chga), IQ motif containing GTPase-activating protein 2 (Iqgap2), interleukin 11 receptor alpha chain 1 (Il11ra1), Micalc C-terminal like (Micalcl), regulator of G-protein signaling 4 (Rgs4), 3 0 -phosphoadenosine 5 0 -phosphosulfate synthase 2 (Papss2), and galactosyltransferase (Galt).
These genes thus defined a regulatory network whose upregulation suppresses prion infection. Next, the authors carried out a series of experiments to explore the cellular roles of the corresponding gene products. Using immunostaining, they found that several of the nine proteins were associated with the extracellular matrix (ECM), including Fn1, Chga, Il11ra1, Itga8, and Micalcl. (Caughey & Raymond, 1993) . In addition, GAGs are known to bind to the N-terminal half of PrP C , thereby enhancing its endocytosis from the cell surface (Shyng et al, 1995) . GAGs also co-localize with PrP Sc deposits in brain.
This work raises a host of interesting questions for future study. Perhaps the most pressing is exactly how upregulation of certain ECM components inhibits prion infection. One possibility is that endogenous GAGs in ECM normally bind to the N-terminal part of PrP C , thereby inhibiting conversion to PrP Sc . ECM GAGs may also bind PrP Sc in the prion inoculum, impeding its access to PrP C on the cell surface and its ability to initiate infection. In either case, downregulating GAG sulfation, or otherwise remodeling the ECM, may reverse these inhibitory processes. These mechanisms would be consistent with the effect of Papss2 gene knockdown, which reduces GAG sulfation. Another hypothesis, suggested by the authors (Fig 1) , is that PrP C deposited in the ECM serves as substrate for the initiation of infection. If this were the case, remodeling of the ECM may allow more PrP C to be deposited there, thereby enhancing PrP C Integrin α8 Itga8
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Other ECM components (collagen, proteoglycans, etc. Marbiah et al (2014) has potentially important therapeutic implications. There are currently no effective treatments for prion diseases, although the utility of PrP knockdown approaches has been demonstrated in experimental animals (White et al, 2008) . The proteins identified in this paper represent novels targets for anti-prion drugs. In this regard, compounds that cause enhanced deposition or stabilization of the ECM might be predicted to reduce or prevent prion infection. In their study, the authors demonstrated that knockdown of ECM-related genes rendered resistant cells more susceptible to infection, but they did not determine whether over-expression of the same genes made susceptible cells resistant. This would clearly be an important first step in developing the novel therapeutic approach suggested here. Aside from their potential clinical relevance, the results presented here may also be helpful to prion biologists, by providing a way to enhance the prion susceptibility of cell types, such as primary neurons, that have been traditionally difficult to infect in culture.
